Molecular Diagnostics Dominated by Five Companies

Top-tier companies are said to continue to dominate due to their global reach and multisegment participation. As in vitro diagnostics (IVD) in North America and Europe offer little growth opportunities for the vast number of tests, the top tier has invested in molecular and personalized medicine testing and has reinforced international connections. The report adds that while the names of the dominating players have not changed extensively in recent years, their revenue growth rates have. High growth has shifted to innovators, while leaders are seeing flatter revenues. For example, “Roche holds the number one market position but growth is slowing,” said Shara Rosen, author of the report. “Roche Diagnostics once earned close to double-digit revenue growth in its molecular test business. This has slowed in the last 2 years.”

The report said that IVD veterans Becton Dickinson, Gen-Probe (now part of Hologic), Abbott Diagnostics, and Siemens Healthcare hold their own in a highly competitive environment, while newcomers Meridian Biosciences and GenMark have made gains with user-friendly, infectious disease tests. Meanwhile, Novartis has stepped out of blood screening to concentrate on other business units.

According to the report, IVD tests are being developed constantly and MD is becoming a go-to resource in clinical practice and is currently the faster-growing part of the diagnostics market.

These and additional findings are published in Kalorama’s "Molecular Diagnostics Six Month Update," the latest, extensive market analysis of the IVD segment, with a bias towards the more developed areas (North America and Western Europe). Given the amount of activity in test development and regulatory and reimbursement challenges, Kalorama focused this update on the last half of 2013.

Related Links:
Kalorama Information
Molecular Diagnostics Six Month Update